Politics, pricing controversy, tax reform and steep valuations conspire to confuse Sanofi’s M&A strategy
One of the big questions facing the industry right now is whether or not the M&A train will get rolling in a meaningful way in 2017. It’s clear that many of the major players — the ones expected to add billions in meaty deals to the bare bones of what we’ve been seeing — have been caught at least somewhat off balance by a new president that constantly spouts off about outrageously high drug costs as well as plans to reform corporate taxes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.